METTL3 and neuroblastoma: In two clinically annotated neuroblastoma cohorts (SEQC-NB [n = 498] and Westermann [n = 105]), superior EFS and OS were observed among patients with tumors with high METTL3 inhibitor response signature scores compared to those with low scores.